Statin myopathy: a common dilemma not reflected in clinical trials.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 21632911.
- Also identified by DOI 10.3949/ccjm.78a.10073.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Although statins are remarkably effective, they are still underprescribed because of concerns about muscle toxicity. We review the aspects of statin myopathy that are important to the primary care physician and provide a guide for evaluating patients on statins who present with muscle complaints. We outline the differential diagnosis, the risks and benefits of statin therapy in patients with possible toxicity, and the subsequent treatment options.